Müllerian adenosarcoma (MA) is a rare malignant tumor of the female reproductive system. Owing to the limited number of clinical cases and the absence of characteristic clinical manifestations, its clinical …
Endometriosis is often diagnosed several years after the first onset of symptoms; however, the duration of this delay may vary depending on the population studied, the assessment starting point, and …
To examine the epistemic injustice experienced by a gender diverse individual during diagnosis for chronic pelvic pain and endometriosis.
Endometriosis is a chronic inflammatory disease associated with pelvic pain, infertility, and delayed diagnosis. Growing evidence suggests that altered DNA methylation contributes to disease development and could serve as a …
Delayed parenthood is a defining feature of contemporary reproductive medicine, fundamentally reshaping reproductive planning and increasing reliance on medically assisted reproduction (MAR). For women of advanced reproductive age (ARA), this …
Endometriosis is a challenging gynaecological condition that can lead to infertility. This unique narrative review summarises the impact of endometriosis, focusing on oocyte quality, its subcellular and molecular mechanisms, clinical …
Herlyn-Werner-Wunderlich syndrome, also known as obstructed hemivagina and ipsilateral renal anomaly (OHVIRA) syndrome, is a rare congenital Müllerian duct anomaly, occurring in approximately 1 in 1,000,000 females. It is characterised …
Pelvic magnetic resonance imaging (MRI) plays an important role in the evaluation of suspected gynecologic malignancies, providing high soft tissue contrast and multiparametric capabilities, including diffusion-weighted imaging and dynamic contrast …
Endometriosis is a debilitating, estrogen-dependent gynecological disorder characterized by profound diagnostic delays due to clinical reliance on invasive laparoscopy. Developing noninvasive, point-of-care biomarker assessment remains a critical yet unmet medical …
Endometriosis affects approximately 10% of reproductive-age women, with a diagnostic delay of 7-10 years. Despite clinical heterogeneity, current rASRM staging poorly predicts treatment outcomes. Molecular subtyping may reveal biologically meaningful …